Latvija - latviešu - Zāļu valsts aģentūra

merck serono, sia, latvia - levotiroksīna nātrija sāls - tablete - 25 μg

Latvija - latviešu - Zāļu valsts aģentūra

merck serono, sia, latvia - levotiroksīna nātrija sāls - tablete - 100 μg

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

nikko yakuhin kogyo co., ltd. - šķidrums

Latvija - latviešu - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - enalaprili maleas, lercanidipini hydrochloridum - apvalkotās tabletes - 10 mg/10 mg

Latvija - latviešu - Zāļu valsts aģentūra

pharmaswiss ceska republika s.r.o., czech republic - enalaprili maleas, lercanidipini hydrochloridum - apvalkotās tabletes - 20 mg/10 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.